drugset / Trial / NCT00060892
Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of this study was to assess the overall safety of different dose regimens of AMG0001 (HGF transferred via plasmid vector) as well as evaluate the improvement of blood perfusion in subjects with critical limb ischemia (CLI). This study also evaluated the improvement in wound healing without adverse effects on the quality of life, as well as the potential reduction of amputation, mortality and rest pain in the CLI population.
Timeline
- Start
- 2003-04
- Primary completion
- 2006-05
- Completion
- 2007-01